DAYBUE net sales projected to reach approx US$700m in 2028
Filed with ASX · · 2 pages · English
Melbourne, Australia: Neuren Pharmaceuticals (ASX: NEU) today reported highlights from the presentation and discussion by its partner Acadia Pharmaceuticals (Nasdaq: ACAD) at the 44th annual J.P. Morgan Healthcare Conference. 1. Rollout of DAYBUE STIX (approved by US FDA in December 2025) that could potentially enable patient growth from families who had declined to try or discontinued the liquid
Neuren Pharmaceuticals Limited on 6ix
Earlier from Neuren Pharmaceuticals
- FDA approves DAYBUE STIX (trofinetide), powder formulation
- Record DAYBUE net sales of US$101.1 million in Q3 2025
- Fast Track granted by FDA for NNZ-2591 in Phelan-McDermid
- Half Yearly Report and Accounts
- First site initiated for Neuren's PMS Phase 3 trial
Later from Neuren Pharmaceuticals
- Response to ASX Aware Letter
- Acadia provides update on EU regulatory submission
- Trading Halt
- Neuren receives US FDA meeting feeback for HIE and PTHS
- First patient dosed in Neuren PMS Phase 3 trial
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals